Drug Approval | May 20, 2023
Strides Puducherry facility receives EIR from USFDA
The USFDA had classified Strides Puducherry facility as OAI in May 2019 followed by issuing a warning letter to this site in July 2019.
The USFDA had classified Strides Puducherry facility as OAI in May 2019 followed by issuing a warning letter to this site in July 2019.
Venlafaxine HCl extended-release capsules are indicated for the treatment of: Major Depressive Disorder
First clinical trial reporting results of an mRNA therapeutic for intracellular protein replacement
Leading Research-driven Pharma Company Combats Antibiotic Resistance and Demonstrates Innovation in Medical Solutions
Farxiga is expected to have such a strong influence on the market due to the impressive results
The Indian pharmaceutical industry includes a network of 3,000 drug companies and 10,500 manufacturing units. It is projected to reach a value of US$ 130 billion by 2030
This latest audit re-emphasizes Hikal's commitment towards maintaining the best in class quality, compliance and regulatory standards across our manufacturing sites
Dr. Reddy's Laboratories has been issued a Form 483 with four observations
VEOZAH is first-in-class treatment option to reduce the frequency and severity of moderate to severe VMS due to menopause
The additional $50 million will go towards venture capital firms that specialize in near- and long-term healthcare solutions for patients in low- and middle-income countries
Subscribe To Our Newsletter & Stay Updated
